Servicio Hepatitis y Gastroenteritis Laboratorio Nacional de Referencia INEI-ANLIS Dr. C. G. MALBRAN Sunrise Symposium at 13 th ISVHLD Washington USA.
Paracentesis
Non-selective Beta blockers
Eugm 2012 unknown - incivex drug development process overview road to finding a cure for hcv genotype 1
1 Kevin P. Cross, Ph.D. Leadscope, Inc. 1393 Dublin Road, Columbus, OH, USA.
BIO-ARTIFICIAL LIVER (EXTRACORPOREAL TEMPORARY LIVER SUPPORT DEVICES) Alan Golde Jr. BME181 March 18 th 2013.
Hepatitis C “Hidden Harm” Prof Suzanne Norris Consultant Hepatologist St James’s Hospital Trinity College Dublin.
How to avoid a resistance issue with the first generation protease inhibitors ? O. Lada PHD Service d’Hépatologie et INSERM CRB3, AP-HP Hopital Beaujon,
John McLinden Biomedical Engineering. A Brief Introduction Liver failure leads to a buildup of toxins in the bloodstream Artificial liver support systems.
Kevin P. Cross, Ph.D. Leadscope, Inc. 1393 Dublin Road, Columbus , OH, USA
Behzad Hajarizadeh, Jason Grebely, Gregory Dore Viral Hepatitis Clinical Research Program
Prevention strategies for HIV/HCV co infection
